| Item Type | Name |
|
Academic Article
|
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
|
|
Academic Article
|
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
|
|
Academic Article
|
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
|
|
Academic Article
|
Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.
|
|
Academic Article
|
CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.
|
|
Academic Article
|
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
|
|
Academic Article
|
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.
|
|
Academic Article
|
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
|
|
Academic Article
|
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.
|
|
Academic Article
|
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation.
|
|
Academic Article
|
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
|
|
Academic Article
|
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
|
|
Academic Article
|
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.
|
|
Academic Article
|
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.
|
|
Academic Article
|
Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12.
|
|
Academic Article
|
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
|
|
Academic Article
|
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.
|
|
Academic Article
|
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.
|
|
Academic Article
|
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.
|
|
Concept
|
Cytomegalovirus Infections
|
|
Concept
|
Herpesvirus 6, Human
|
|
Concept
|
Cytomegalovirus
|
|
Concept
|
Herpesvirus 4, Human
|
|
Concept
|
Herpesvirus 3, Human
|
|
Academic Article
|
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
|
|
Academic Article
|
Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
|
|
Academic Article
|
T lymphocytes targeting native receptors.
|
|
Academic Article
|
Systemic inflammatory response syndrome after administration of unmodified T lymphocytes.
|
|
Academic Article
|
Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.
|
|
Academic Article
|
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
|
|
Academic Article
|
Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients.
|
|
Academic Article
|
Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
|
|
Academic Article
|
Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections.
|
|
Academic Article
|
Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant Recipients.
|
|
Academic Article
|
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting.
|
|
Academic Article
|
Assessment of the cytolytic potential of a multivirus-targeted T cell therapy using a vital dye-based, flow cytometric assay.
|